Survodutide

01 · What it is

Survodutide has the most complete phase 3 programme of any unapproved compound in this project, and its drug class has already lost a member to a cardiac safety problem.

A 2026 narrative review in the Journal of the American Heart Association, focused specifically on glucagon-receptor signalling in multi-agonists, records that survodutide and mazdutide reduced blood pressure and hyperglycaemia — and, in the same passage, that at least one other dual agonist was discontinued, partly because of unacceptably large increases in heart rate and prolongation of the corrected QT interval ¹⁸.

The same review reports the balancing fact, and it belongs here rather than buried: survodutide and mazdutide themselves increased heart rate to a similar extent as GLP-1 receptor monoagonists, which are cardioprotective despite that effect ¹⁸. The discontinued compound is a different molecule.

Both sentences matter. Glucagon-receptor agonism is being pursued because it appears to change the character of weight loss, not only its size. It is also the receptor arm where a compound in this class has already failed on cardiac grounds — which is the reason survodutide’s own cardiovascular outcome trial, still ongoing ¹², is the thing worth waiting for rather than a formality.

What it is. Survodutide is a glucagon receptor / GLP-1 receptor dual agonist under investigation for obesity and related disease ¹⁵. A plain-language review states directly that it is not yet approved for use ⁹.

The programme. SYNCHRONIZE-1 randomised 725 adults with obesity — 241 to survodutide 3.6 mg, 242 to 6.0 mg and 242 to placebo, mean age 47.1 years, 40.6% men — and reported no deaths ¹⁰. SYNCHRONIZE-MASLD was a randomised, double-blind, placebo-controlled phase 3 trial in obesity with at-risk steatotic liver disease, in which the compound was statistically and clinically superior to placebo on its stated endpoint ¹⁵. Two further phase 3 trials have published design and baseline papers, in Japan ¹⁴ and in China ¹⁹. A phase 2 MASH trial has a published mediation analysis ¹⁷.

This guide could not read SYNCHRONIZE-1’s efficacy result. The abstract text retrieved here is truncated mid-conclusion. The trial’s structure and its headline safety statement are reported above; its weight-loss figure is not, because this guide does not have it.

02 · Evidence at a glance

Evidence grade

Early Clinical — multiple phase 3 trials, one reported; no marketing authorisation

Approval status

Not yet approved for use ⁹

What it is

A glucagon receptor / GLP-1 receptor dual agonist ¹⁵

Class safety signal

At least one other dual agonist discontinued, partly for unacceptably large heart-rate increases and QT prolongation ¹⁸

Survodutide’s own heart-rate effect

Similar in extent to GLP-1 monoagonists, which are cardioprotective despite it ¹⁸

SYNCHRONIZE-1

725 participants: 241 (3.6 mg), 242 (6.0 mg), 242 placebo; mean age 47.1; 40.6% men; no deaths reported ¹⁰

SYNCHRONIZE-1 efficacy figure

Truncated in the record read here — not reported in this guide

SYNCHRONIZE-MASLD

Randomised, double-blind, placebo-controlled phase 3 in obesity with at-risk MASLD; statistically and clinically superior to placebo ¹⁵

SYNCHRONIZE-JP

Phase 3 design and baseline; 1:1:1 to 3.6 mg, 6.0 mg or placebo with reduced-calorie diet and increased activity ¹⁴

SYNCHRONIZE-CN

Phase 3 design and baseline, Chinese adults (NCT06214741) ¹⁹

Phase 2 MASH

Mediation analysis of liver endpoints in fibrosis stage F2–F3 with paired biopsies (NCT04771273) ¹⁷

Fibrosis network meta-analysis

Survodutide 6 mg/week ranked first (SUCRA 92.0%), tirzepatide 15 mg second (89.9%), emricasan last (8.1%) ⁸

Polyagonist MASH meta-analysis

RR 3.32 (95% CI 2.28–4.84; I² = 20%) for resolution or histological improvement, pooled across five compounds ¹¹

Beta-cell and insulin sensitivity

Trial 1404-0002, 413 participants, 16 weeks, versus placebo and semaglutide; trial 1404-0036, 387 participants ²⁰

Preclinical mechanism

Acts through circumventricular organs; fluorophore-labelled compound used to visualise sites of action ³

Liver fat

60–80% reductions attributed to glucagon-containing agents as a group ¹⁶

Cardiovascular outcome trial

Ongoing, per a 2026 review of pipeline agents ¹²

03 · Mechanism of action

The glucagon receptor is the point, and the risk

Survodutide agonises both the glucagon receptor and the GLP-1 receptor ^15,20. A 2026 IUPHAR review frames the whole strategy — From foe to friend: repurposing glucagon to treat obesity and type 2 diabetes — and places survodutide among the dual agonists built on it ¹.

The pharmacological bet is that glucagon-receptor agonism adds energy expenditure and hepatic effects that GLP-1 agonism alone does not produce. The pharmacological hazard is that glucagon has cardiovascular actions, and the class has already produced a discontinuation on exactly those grounds ¹⁸.

Where it acts, shown rather than inferred

A 2026 preclinical study reports that survodutide acts through circumventricular organs and activates neuronal regions associated with appetite regulation, with body-weight lowering achieved through decreased energy intake and increased energy expenditure. The authors used a fluorophore-labelled survodutide to visualise sites of action directly, and note that the GLP-1 receptor is expressed in the tissues examined ³.

Labelling the molecule and looking at where it goes is a stronger method than inferring a site of action from a downstream readout, and this project has covered many compounds where the latter was all that existed. The two-part effect — intake down and expenditure up — is also the specific signature glucagon-receptor agonism is supposed to produce, so the preclinical result is consistent with the design rationale rather than merely compatible with it.

The metabolic effects, measured on biomarkers

Two randomised trials examined beta-cell function and insulin sensitivity: trial 1404-0002 randomised 413 participants with type 2 diabetes on metformin to survodutide, placebo or semaglutide over 16 weeks; trial 1404-0036 randomised 387 participants with overweight or obesity and normoglycaemia ²⁰.

A semaglutide comparator arm in a mechanism trial is worth noting — it makes the biomarker comparison interpretable rather than merely descriptive. The endpoints are still biomarkers of beta-cell function and insulin sensitivity, not clinical outcomes.

04 · Key research findings

Obesity

SYNCHRONIZE-1, 2026. Among 725 participants — 241 in the 3.6 mg group, 242 in the 6.0 mg group and 242 on placebo — the mean age was 47.1 years and 294 participants (40.6%) were men. No deaths were reported ¹⁰.

The efficacy conclusion is truncated in the record available here and is therefore absent from this guide. Reporting the demographics and the mortality statement while omitting the effect size is unsatisfying and correct.

SYNCHRONIZE-JP, 2026. A phase 3 trial in Japanese participants, randomising 1:1:1 to once-weekly survodutide 3.6 mg or 6.0 mg, or placebo, each accompanied by a reduced-calorie diet and increased physical activity, intended to provide Japan-specific efficacy, safety and tolerability data ¹⁴.

SYNCHRONIZE-CN, 2026. A phase 3 trial in Chinese adults with overweight or obesity (NCT06214741), published as rationale, design and baseline characteristics ¹⁹.

Two separate regional phase 3 trials with published design papers is a marker of a serious registration programme. It is also the reason this compound’s literature looks large: much of it describes trials rather than reporting them.

Trial-conduct research, 2026. A clinical trial simulation conducted for three SYNCHRONIZE trials, involving individuals meeting the inclusion criteria and clinical trial professionals, aimed at optimising participant and site engagement ².

Included because it is unusual and revealing. A published methods study on how to recruit for the programme is the kind of literature that only exists around a well-resourced late-stage development effort, and it inflates the apparent publication count without adding evidence about the drug.

Liver

SYNCHRONIZE-MASLD, 2026. A randomised, double-blind, placebo-controlled phase 3 trial in adults with obesity and at-risk metabolic dysfunction-associated steatotic liver disease. Survodutide treatment was statistically and clinically superior to placebo on the endpoint reported ¹⁵.

Phase 2 MASH mediation analysis, 2026. Survodutide was associated with improvements in liver-related endpoints in a phase 2 trial (NCT04771273); the mediation analysis examined weight-reduction-dependent and weight-reduction-independent effects, using data from participants with fibrosis stage F2–F3 and paired baseline and end-of-treatment biopsy readings ¹⁷.

This is the most interesting design in the guide. If a drug’s liver benefit is entirely mediated by weight loss, it is a weight-loss drug with a liver readout. If part of the effect is independent of weight change, the glucagon-receptor rationale has direct support. The analysis was built to distinguish those cases, and paired biopsies are the right instrument. This guide has read the abstract’s framing, not its result.

Fibrosis network meta-analysis, 2026. Across pharmacotherapies for fibrosis stages F1–F3 in steatotic liver disease, SUCRA ranking placed survodutide 6 mg/week first at 92.0%, tirzepatide 15 mg/week second at 89.9%, and emricasan 10 mg/day last at 8.1% ⁸.

A SUCRA ranking is a probability of being the best treatment in a network, not an effect size, and first place in a network built largely from small and heterogeneous trials should not be read as established superiority. It is a real signal reported in its own terms.

Polyagonist meta-analysis, 2026. Tirzepatide, survodutide, pemvidutide, retatrutide and cotadutide together significantly increased MASH resolution or histological improvement without worsening of fibrosis (RR 3.32, 95% CI 2.28–4.84; I² = 20%) ¹¹.

Pooled across five distinct molecules. The low heterogeneity is notable; the class-level pooling still means this is not a survodutide result.

MASH-cirrhosis trials, 2026. A review of lessons learned lists survodutide among ongoing studies alongside efruxifermin and the conditionally approved resmetirom ⁷.

The synthesis for this system: survodutide’s liver evidence is its strongest suit — a positive phase 3, a mechanistically pointed mediation analysis, and a first-place network ranking. It is also where the compound is least replaceable by a plain GLP-1 agonist, which is why the mediation result matters more than the ranking.

Cardiovascular and class-level

Glucagon-receptor cardiovascular review, 2026. Clinical studies of glucagon/GLP-1 dual agonists, naming mazdutide and survodutide, have generally found that they increased heart rate to a similar extent as GLP-1 receptor monoagonists — which are cardioprotective despite that chronotropic effect. Mazdutide and survodutide also reduced blood pressure and hyperglycaemia. The same review records that at least one other dual agonist was discontinued, partly due to unacceptably large increases in heart rate and prolongation of the corrected QT interval ¹⁸.

Both halves belong in the same paragraph, and the first materially softens the second. The discontinued compound is a different molecule; the heart-rate effect measured for survodutide itself sits in the same range as agents with established cardiovascular benefit. The precedent is a reason the outcome trial matters, not a finding against this compound.

Pipeline cardiovascular review, 2026. Survodutide is reviewed alongside retatrutide, CagriSema, orforglipron, zenagamtide and MariTide, together with their ongoing cardiovascular outcome trials ¹².

Glucagon-receptor agonist network meta-analysis, 2026. Across investigational agents including retatrutide, cotadutide, mazdutide and survodutide, retatrutide showed the largest HbA1c reduction, followed by survodutide ⁴.

The synthesis: the cardiovascular position is a genuinely open question with a live adverse precedent in the same receptor class and an outcome trial not yet reported. Blood-pressure reduction is favourable; heart rate and QT are the variables that ended a sibling compound.

Reviews and positioning

Reviews describe survodutide as an innovative approach to obesity and fatty liver disease ⁵, place dual GLP-1/glucagon agonists alongside triple agonists in a reimagined pharmacotherapy landscape with particular promise in liver disease ⁶, attribute liver-fat reductions of roughly 60–80% to glucagon-containing agents as a group ¹⁶, and synthesise multisystem benefits across approved and late-stage investigational obesity medications ¹³.

Six reviews to one reported phase 3 trial is the ratio this literature currently has. Review volume tracks commercial interest, not evidence.

05 · Evidence overview

06 · Safety profile

This section reports the existence and structure of the safety literature. It does not enumerate adverse effects or offer guidance. There is no product label, because there is no approval.

Animal data. A preclinical study characterises sites of action and the components of the body-weight effect ³. No dedicated toxicology study was retrieved in this search.

Human data. SYNCHRONIZE-1 reports no deaths among 725 randomised participants ¹⁰. Safety and tolerability are stated objectives of the Japanese and Chinese phase 3 trials ^14,19 and of the mechanism trials ²⁰. Blood pressure and hyperglycaemia were reduced ¹⁸.

The class signal, stated plainly and in full. At least one other glucagon/GLP-1 dual agonist was discontinued, in part because of unacceptably large increases in heart rate and prolongation of the corrected QT interval ¹⁸. The same review reports that survodutide and mazdutide themselves increased heart rate to a similar extent as GLP-1 receptor monoagonists, which are cardioprotective despite that effect ¹⁸. The review does not name the discontinued compound and does not attribute its effects to survodutide.

This project’s rule is that limitations get stated as prominently as findings. A discontinuation for QT prolongation in a sibling compound is not evidence against survodutide; it is the specific reason its cardiovascular outcome trial matters, and the specific thing an unmonitored setting could not detect.

What is genuinely unknown. Four items.

Cardiovascular outcomes. The trial is described as ongoing ¹². Until it reports, nothing about cardiovascular benefit or harm is established for this compound.

Heart rate and QT for survodutide specifically. The located literature reports the class precedent ¹⁸ but this guide retrieved no survodutide-specific cardiac electrophysiology data.

The SYNCHRONIZE-1 efficacy and adverse-event profile. Truncated in the record read here.

Anything outside a trial. No published analysis located here examines any survodutide-labelled material obtained outside a clinical trial. The compound is unapproved, so no regulated supply chain for human use exists.

07 · US regulatory status

Current as of 7 September 2026. Survodutide is not approved for use ⁹. It is under investigation in a multi-region phase 3 programme ^10,14,15,19, with a cardiovascular outcome trial described as ongoing ¹².

This guide has not consulted FDA or EMA records, and reports registry identifiers only as they appear in the cited publications (NCT04771273 ¹⁷; NCT06214741 ¹⁹).

An unapproved drug cannot lawfully be supplied for human use in the United States outside an authorised clinical trial or a formal expanded-access pathway.

Under the World Anti-Doping Code, competitors should consult the current Prohibited List directly rather than rely on secondary summaries, including this one.

08 · Limitations of the evidence

1. A sibling compound in the same receptor class was discontinued for cardiac reasons — heart-rate increases and QT prolongation described as unacceptably large ¹⁸. This is the most important context for the compound and it belongs at the top of the limitations, not buried.
2. The cardiovascular outcome trial has not reported ¹². Every cardiovascular statement available for survodutide concerns blood pressure and glycaemia, which are risk markers.
3. This guide could not read SYNCHRONIZE-1’s efficacy result ¹⁰. The trial is cited for its design, demographics and mortality statement only. Full-text retrieval is a verification item.
4. Two of the four phase 3 trials are represented by design papers, not results ^14,19. A published protocol is a commitment, not a finding.
5. The fibrosis first-place ranking is a SUCRA probability ⁸, derived from a network of heterogeneous trials, and is not a head-to-head result against tirzepatide.
6. The polyagonist liver meta-analysis pools five different compounds ¹¹. Its RR 3.32 is a class estimate.
7. The mediation analysis result is not reported here ¹⁷, only its design. Whether the liver effect is independent of weight loss is the central mechanistic question for this compound and this guide does not answer it.
8. No dedicated toxicology study was retrieved.
9. No long-term data were located. The longest exposure identifiable from the records read here is within the phase 3 trials, whose durations were not captured in the abstracts examined.
10. Sponsor involvement is pervasive, with recurring investigator groups and industry-affiliated authors across the SYNCHRONIZE programme, the mechanism trials and the trial-conduct study ^{2,10,14,15,17,19,20}, as is normal at this stage of development.
11. Reviews outnumber reported trials in this guide by roughly three to one ^{1,5,6,7,12,13,16,18}, which inflates apparent evidence volume.
12. Twenty of 74 records were examined, and this guide has read abstracts, not full texts.

09 · Legal and regulatory appendix

This appendix applies to every compound in this family and is reproduced in each guide.

Approval status. Survodutide is not approved for use ⁹. Supplying or administering an unapproved drug for human use is unlawful in the United States and in most other jurisdictions outside an authorised trial or expanded-access pathway. This guide does not describe how to obtain the compound and takes no position on any supplier.

Products sold under this name. Material sold as survodutide outside a clinical trial has no established relationship to the material used in the studies cited here. This guide located no published analysis of the identity, purity, concentration, sterility or contamination status of any such product. Nothing in the trial evidence described above should be read as applying to it.

Research-use labelling. Material labelled for laboratory research use is not manufactured, tested, or released to the standards applied to medicines intended for people, and such labelling does not make administration lawful or safe.

What this guide is. A description of the published peer-reviewed literature, written for readers who want to understand the state of the evidence. It is not medical advice, not a recommendation, not an endorsement, and not a substitute for a clinician who can assess an individual situation.

Editorial position. Arkham Labs publishes independently and earns through disclosed referral links. That commercial relationship is disclosed on every page carrying such a link and on the editorial standards page. It does not alter what the evidence says, and this guide leads with a cardiac discontinuation in the compound’s own drug class.

10 · References

1. Elmendorf AJ, Yousefian M, Kim IM, Hardaway JA, Habegger K, Flak JN. IUPHAR review: from foe to friend: repurposing glucagon to treat obesity and type 2 diabetes. Pharmacol Res. 2026 Jan;223:108077. Review.

   PMID 41478576 ↗

2. Rubino DM, Mooney V, van de Walle V, Baanstra D, Daniëls W, Recaldin C, Nadglowski J. Optimization of patient and site engagement in the SYNCHRONIZE phase 3 clinical trial program for survodutide in obesity through clinical trial simulation. Contemp Clin Trials Commun. 2026 Feb 4;49:101611.

   PMID 41704810 ↗

3. Zimmermann T, Bleymehl K, Haebel P, Perens J, Roostalu U, Hecksher-Sørensen J, Doerr J, Jarosch S, Lam D, Klein H, Pekcec A, Chehimi SN, Crist RC, Reiner BC, Hayes MR, Augustin R. Survodutide acts through circumventricular organs in the brain and activates neuronal regions associated with appetite regulation. Mol Metab. 2026 Mar;105:102326.

   PMID 41638399 ↗

4. Abulehia A, Ayesh H, Ayesh O, Jaber D, Asad T, Itbaisha A, Abugharbieh H, Gharbia R, Abu-Hilal LH, Leon BGC. Comparative efficacy and safety of glucagon receptor agonists on metabolic outcomes: a network meta-analysis of randomised controlled trials. Endocrinol Diabetes Metab. 2026 Mar;9(2):e70187. Review.

   PMID 41787737 ↗

5. Yathindra MR, Bhattacharjee A, Pundir N, Patel P, Jacob NE, Jossy PE, Seetharaman R. A review of survodutide: a new dual acting agonist. Minerva Endocrinol (Torino). 2026 Mar 19.

   PMID 41855048 ↗

6. Lempesis IG, Dalamaga M. Obesity pharmacotherapy reimagined: the era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies. Metabol Open. 2026 Mar 23;30:100463. Review.

   PMID 41948476 ↗

7. Patil R, Dunn W, Noureddin M, Alkhouri N. Metabolic dysfunction-associated steatohepatitis (MASH)-cirrhosis clinical trials: lessons learned and future directions. Drugs. 2026 May;86(5):627–643. Review.

   PMID 41831171 ↗

8. Sun XY, Jiang HL, Ma YT, Xiong TQ, Leng XY, Zhao YF, Shen XF, Zhang C, Tang YJ. Efficacy of pharmacotherapies in improving liver fibrosis among patients with MASLD and fibrosis stages of F1-F3: systematic review and network meta-analysis. J Transl Med. 2026 May 26;24(1):931.

   PMID 42192439 ↗

9. Almandoz JP, Miras AD, Seufert J, Paul E. How does survodutide work? Plain language review of a potential new medication for obesity and liver disease. Ther Adv Gastroenterol. 2026 Jun 5;19:17562848261457269. Review.

   PMID 42254697 ↗

10. le Roux CW, Wharton S, Startseva E, Kloer IM, Hussain SA, Unseld A, Bozkurt B, Ard JD, Bays HE, Bogdański P, Ekinci EI, Jastreboff AM, Ji L, Ogawa W, Pedersen SD, Pietiläinen KH, Sattar N, Seufert J, Stenlöf K, van Beek AP, Vangoitsenhoven R, Brueckmann M, Younes R, Kaplan LM; SYNCHRONIZE-1 Investigators. Survodutide once weekly for the treatment of adults with obesity. N Engl J Med. 2026 Jun 7.

    PMID 42253238 ↗

11. Santos Solis R, Baeza-Zapata AA, Negrete-Najar JP. Efficacy and safety of dual and triple glucagon-like peptide-1-based polyagonists in metabolic dysfunction-associated steatotic liver disease and steatohepatitis: a systematic review and meta-analysis. Cureus. 2026 Jun 29;18(6):e111728. Review.

    PMID 42529769 ↗

12. Araiza-Garaygordobil D, Rico-Fontalvo J, Hernández-Balbuena B, Vinay-Coro M, González-Arias M. Incretin analogues as cardiovascular agents: a state-of-the-art review. Front Endocrinol (Lausanne). 2026 Jul 24;17:1898812. Review.

    PMID 42568490 ↗

13. Savas M, Kuckuck S, Boon MR, van Rossum EFC. Beyond weight loss: multisystem benefits of obesity medications. Lancet Diabetes Endocrinol. 2026 Aug;14(8):678–692. Review.

    PMID 42208956 ↗

14. Yokote K, Yamauchi T, Fukushima Y, Takatsuka Y, Kato M, Yan S, Inoue T, Borowska L, Brueckmann M, Ogawa W; SYNCHRONIZE-JP Trial Investigators. Survodutide for the treatment of obesity disease in Japanese participants: rationale, design and baseline characteristics of the phase 3 SYNCHRONIZE-JP trial. Diabetes Obes Metab. 2026 Aug;28(8):6595–6606.

    PMID 42219222 ↗

15. Kaplan LM, Startseva E, le Roux CW, Wharton S, Bozkurt B, Mazo DF, von Schlippenbach J, González Maldonado S, Ajaz Hussain S, Neff GW, Gonzalez Rojas Y, Smith C, Younes R, Sanyal AJ; SYNCHRONIZE-MASLD Investigators. Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med. 2026 Aug;32(8):2948–2958.

    PMID 42252333 ↗

16. Bijoch J. Anti-obesity medications in longevity and aesthetic medicine. J Clin Med. 2026 Aug 3;15(15):6026. Review.

    PMID 42590128 ↗

17. Noureddin M, Sanyal AJ, Bedossa P, Fraessdorf M, Schoelch C, Startseva E, Marshall R, Alhussein A, Neff GW, Lawitz EJ, Bugianesi E, Anstee QM, Newsome PN, Ratziu V, Hosseini-Tabatabaei A, Schattenberg JM, Alkhouri N, Younes R. Weight reduction-dependent and -independent effects of survodutide on liver endpoints: mediation analysis of a phase 2 trial in MASH. Hepatology. 2026 Aug 3.

    PMID 42545725 ↗

18. Kushner PR, Michos ED. Cardiovascular effects of glucagon receptor signaling alone and combined with glucagon-like peptide-1 receptor signaling in multiagonists: a narrative review with a translational focus. J Am Heart Assoc. 2026 Aug 4;15(15):e049727. Review.

    PMID 42535526 ↗

19. Ji L, Chen L, Cheng Z, Lu Y, Yang Y, Fu F, Zhu Y, Jin L, Kloer IM. Survodutide for obesity in Chinese adults: phase 3 randomized trial design and baseline characteristics (SYNCHRONIZE-CN). Diabetes Ther. 2026 Aug 14.

    PMID 42599381 ↗

20. Ekinci EI, Maldonado SG, Unseld A, Martinez JA, Hennige AM, Schoelch C. Dual glucagon and GLP-1 receptor agonist survodutide improves biomarkers of beta-cell function and insulin sensitivity in people with type 2 diabetes or living with overweight/obesity. Diabetes Obes Metab. 2026 Sep;28(9):8242–8253.

    PMID 42331726 ↗